Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Change in Accured Expenses of -$7.8 million for Q1 2026, down 1028.06% year-over-year from $841000.0 in Q1 2025, and down 2563.82% quarter-over-quarter from -$293000.0 in Q4 2025.
Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Scilex Holding's Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$7.8 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 1028.06% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at $6.0 million (up 170.51% YoY), while the FY2025 annual figure was $14.6 million, up 278.78% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$7.8 million, down from -$293000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $14.3 million in Q3 2025, with the low at -$10.6 million in Q4 2024.
- The 5-year median for Change in Accured Expenses is -$137000.0 (2022), against an average of $32176.5.
- Peak annual rise in Change in Accured Expenses reached 14054.56% in 2022, while the deepest fall reached 12953.93% in 2022.
- Scilex Holding's Change in Accured Expenses stood at -$137000.0 in 2022, then sank by 2246.72% to -$3.2 million in 2023, then sank by 230.64% to -$10.6 million in 2024, then jumped by 97.24% to -$293000.0 in 2025, then tumbled by 2563.82% to -$7.8 million in 2026.
- Business Quant data shows SCLX's Change in Accured Expenses at -$7.8 million in Q1 2026, -$293000.0 in Q4 2025, and $14.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 852.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 338.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.81 Mn |
| Mar 31, 2026 | -7.81 Mn |
| Dec 31, 2025 | -293,000.00 |
| Dec 31, 2025 | -293,000.00 |
| Sep 30, 2025 | 14.30 Mn |
| Sep 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | -242,000.00 |
| Jun 30, 2025 | -242,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Dec 31, 2024 | -10.63 Mn |
| Dec 31, 2024 | -10.63 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | -650,000.00 |
| Jun 30, 2024 | -650,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | -3.22 Mn |
| Dec 31, 2023 | -3.22 Mn |